Urovant Sciences Ltd

U.S. Zulassung für GEMTESA® (vibegron)

• überaktive Blase
  

https://ir.urovant.com/news-releases/news-release-details/urovant-sciences-announces-us-fda-approval-gemtesar-vibegron-75

https://www.nasdaq.com/articles/urovant-sciences-is-a-hidden-gem-with-a-blockbuster-drug-likely-to-be-approved-this-year

• Sumitovant hält 72% der Anteile
  
• bietet für die restlichen 28% rund 16,25$ je Aktie in Bar
  
• Premium 96%
  

https://seekingalpha.com/news/3635918-sumitovant-biopharma-to-acquire-balance-shares-in-urovant-sciences-for-16_25-share

neue Besitzverhältnisse durch Roivant-Sumitomo Deal

https://www.pmlive.com/pharma_news/sumitomo_dainippon_goes_big_on_biotech_with_$3bn_roivant_deal_1301080